The Vaccine and Cell Therapy Core Laboratory is a new shared resource at the NYU Cancer Institute that is an essential part of the recently established Tumor Vaccine Program. The purpose of the laboratory is to support clinical trials of experimental immunotherapies for cancer and chronic viral infections such as HIV/AIDS at NYU Medical Center and at collaborating institutions. It does this by providing two types of services. First, the laboratory prepares vaccines and cellular immunotherapies in a dedicated, controlled space in accordance with current Good Manufacturing Practice (cGMP) regulations as required by the US Food and Drug Administration (FDA). This GMP laboratory features three class 10,000 (ISO 7) cleanrooms, and has been designed with the flexibility to manufacture virtually any type of therapy that uses manipulated human cells. It is one of only a handful of such laboratories in the Greater New York metropolitan region. Second, the Core also features a very well equipped Immunology Laboratory that offers a variety of sophisticated immune monitoring technologies and services to measure patients'responses to vaccination. The Vaccine and Cell Therapy Core opened.in early 2006, and currently supports three immunotherapy trials for cancer at NYU and two HIV vaccine trials at Massachusetts General Hospital. A fourth cancer immunotherapy trial at NYU is planned for the fourth quarter of 2006. We anticipate an expanding user base over the next few years as the Tumor Vaccine Program continues to grow, and as an increasing number of investigators begin to take advantage of this remarkable resource.
| Formenti, Silvia C; Lee, Percy; Adams, Sylvia et al. (2018) Focal Irradiation and Systemic TGF? Blockade in Metastatic Breast Cancer. Clin Cancer Res 24:2493-2504 |
| Snuderl, Matija; Kannan, Kasthuri; Pfaff, Elke et al. (2018) Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nat Commun 9:2868 |
| Stafford, James M; Lee, Chul-Hwan; Voigt, Philipp et al. (2018) Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma. Sci Adv 4:eaau5935 |
| Lee, Chul-Hwan; Yu, Jia-Ray; Kumar, Sunil et al. (2018) Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. Mol Cell 70:422-434.e6 |
| Aiello, Nicole M; Maddipati, Ravikanth; Norgard, Robert J et al. (2018) EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell 45:681-695.e4 |
| Jung, Heekyung; Baek, Myungin; D'Elia, Kristen P et al. (2018) The Ancient Origins of Neural Substrates for Land Walking. Cell 172:667-682.e15 |
| Herline, Krystal; Prelli, Frances; Mehta, Pankaj et al. (2018) Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimers Res Ther 10:54 |
| Xu, Mo; Pokrovskii, Maria; Ding, Yi et al. (2018) c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554:373-377 |
| Snetkova, Valentina; Skok, Jane A (2018) Enhancer talk. Epigenomics 10:483-498 |
| Litwinoff, Evelyn M S; Gold, Merav Y; Singh, Karan et al. (2018) Myeloid ATG16L1 does not affect adipose tissue inflammation or body mass in mice fed high fat diet. Obes Res Clin Pract 12:174-186 |
Showing the most recent 10 out of 1170 publications
